King Pharma Sues Sandoz Over Generic EpiPen

Law360, New York (July 16, 2010, 12:25 PM EDT) -- EpiPen maker King Pharmaceuticals Inc. has lodged a complaint against Novartis AG's Sandoz Inc. unit, seeking to block the generic-drug maker from making and selling its own version of the epinephrine auto-injector.

King filed suit Wednesday in the U.S. District Court for the District of New Jersey, accusing Sandoz of infringing U.S. Patent Number 7,449,012 B2 by seeking U.S. Food and Drug Administration Approval to launch a generic version of EpiPen prior to the patent's 2025 expiration.

The plaintiff acquired rights to EpiPen, an auto-injector used...
To view the full article, register now.